ABSTRACT: Microcystins (MCs) are highly toxic natural products which are produced by cyanobacteria. They can be released to the water during harmful algal blooms and are a serious threat to animals and humans. Described is the total synthesis of the cyanotoxin microcystin-LF (MC-LF, 1a) and two derivatives thereof. Deuterated derivative 1b is of interest as an internal standard during MC quantification in biological samples by mass spectrometry and alkyne-labeled 1c can be employed for toxin derivatization by click chemistry with an azide-containing reporter molecule or as an activity-based probe to identify interaction partners. Application of tert-butyl ester protecting groups for erythro-β-D-methylaspartic acid and γ-D-glutamic acid were key for an isomerization-free synthesis. The analytical data of synthetic MC-LF were identical to those of an authentic sample of the natural product. All derivatives 1a−c were determined to be potent inhibitors of protein phosphatase-1 with similar activity.
■ INTRODUCTION
Microcystins (MCs) are highly toxic natural products which are produced by cyanobacteria and, according to the WHO, are among the most dangerous water pollutants. 1 Widespread harmful algal blooms in densely populated areas, which are favored by global warming along with eutrophication of surface waters, 2 resulted in a shutdown of the public water supply for millions of people, for example in Toledo, Ohio, USA, (August 2014) and around lake Taihu in China (July 2007) . 2, 3 The sole analytical method for congener-specific MC detection enabling the identification and quantification of MCs is liquid chromatography−mass spectrometry/mass spectrometry (LC-MS/MS). 2b,4 However, the lack of certified reference compounds limits the applicability of this method.
2b Although research on MCs has been conducted since 1878, 5 their physiological function in cyanobacteria is still under scientific debate. 6 Consequently, the total synthesis of MCs would provide access to a yet missing variety of reference compounds as well as microcystin derivatives for structure−activity relationship studies enabling future studies into the biological roles of MCs. Furthermore, the high cytotoxicity of MCs makes this scaffold an attractive lead structure for the development of novel potent anticancer drugs.
As shown in Figure 1 , MCs consist of three D-amino acids in positions 1, 3, and 6, the β-amino acid Adda5, and Nmethyldehydroalanine (Mdha7) which is involved in covalent binding of MCs to ser/thr protein phosphatases by Michael addition of a proximate cysteine residue.
7 Two L-amino acids in positions 2 and 4 are variable and account for the major differences amongst the more than 100 individual congeners, that have been reported so far. 8 Despite numerous attempts 9 the total synthesis of a natural microcystin (MC-LA) was accomplished only once. 10 This landmark achievement featured protection of β-D-MeAsp3 and γ-D-Glu6 by methyl esters that were cleaved under basic conditions in the last synthetic step. Unfortunately, this treatment led to the formation of several uncharacterized isomers of the final product. 10 In our interpretation the isomerization can be attributed to a cyclization involving β-D-MeAsp3 (I, Scheme 1) leading to aspartimide II which is prone to isomerization at the chiral centers in the α-and β-positions. Ring opening by basic hydrolysis can lead to the stereoisomers III of desired MC-LA as well as constitutional isomers IV. Despite extensive investigation of different methyl ester cleavage conditions, the isomerization could not be avoided and resulted in significant loss of material. 10 To identify natural MC-LA, the isomeric mixture was separated by HPLC and the isomers were compared to an authentic sample of the cyanotoxin. 10 The identification of the desired isomers was particularly intricate during the synthesis of unnatural derivatives for which no standard was available. 11 Here, we present an isomerization-free synthetic strategy and its application to the first total synthesis of MC-LF (1a) and its deuterated derivative 1b (Scheme 2) which is of interest as an internal standard during MC quantification by mass spectrometry. Since this approach delivers only one isomer, the synthesis of unnatural MC derivatives becomes feasible which we demonstrate by the preparation of derivative 1c. The alkynelabeled 1c can be employed for toxin derivatization by click chemistry with an azide-containing reporter molecule, e.g., biotin or a fluorescent dye, and, furthermore, be used as an activity-based probe to identify interaction partners.
12 According to crystal structures of MCs in complex with ser/thr protein phosphatases 13 the side chain at position 4 of the MC backbone is not involved in binding and thus represents an optimal position for synthetic modifications.
■ RESULTS AND DISCUSSION
Retrosynthetic Analysis. For the synthesis of 1a−c we followed a fragment-based strategy using tert-butyl esters as protecting groups for β-D-MeAsp3 and γ-D-Glu6 in order to suppress aspartimide formation.
14 In contrast to the previous approach, 10 in which N-methylphosphonylsarcosine was incorporated and subsequently converted into Mdha7 by a Horner−Wadsworth−Emmons reaction, we incorporated Nmethylphenylselenocysteine (NMeSecPh) as Mdha precursor that was transformed into Mdha in the final step of the synthesis. For the macrocyclization, we decided to use the peptide bond between residues 4 and 5 which is also the cyclization site during biosynthesis of MCs. 15 In addition, this disconnection has proven reliable in the former synthetic approach.
tert-butyl ester and the phenylselenocysteine moiety in fragments 4 and 5a−c required a C-terminal protection which can be cleaved in the presence of these three groups and withstands the conditions of Fmoc deprotection. In our approach we used the phenacyl (Pac) protecting group which is removed under mild reductive conditions. 17 Tetrapeptide 4 and dipeptides 5a−c were obtained from NMeSecPh derivative 6, 18 β-D-MeAsp derivative 7 and the building blocks 8a, 17 8b, and 8c.
Synthesis of Tetrapeptide 4. We started our synthesis with the preparation of tetrapeptide fragment 4 (Scheme 3).
Boc-NMeSecPh−OH 6 was synthesized starting from Boc-Nmethyl-L-serine 9 using the strategy developed by van der Donk and co-workers for the synthesis of Boc-SecPh−OH 19 and coupled with dipeptide 11 to give 12. 18 Tripeptide 12 was then deprotected with TFA and coupled with Fmoc-D-Glu-Ot-Bu to give fragment 4.
Synthesis of Dipeptides 5a−c. In position 3 of the vast majority of the MCs erythro-β-methyl D-aspartic acid (DMeAsp) is found. Up to date several synthetic routes toward derivatives of this amino acid have been published. 10,16e−g,20 However, all these published approaches feature methyl or ethyl ester protecting groups, which are crucial for the generation of the stereocenter at the β-carbon atom. Since the literature-known building blocks cannot be easily transformed into 7, we synthesized Fmoc-D-MeAsp-Ot-Bu 7 starting from D-aspartic acid 13 as shown in Scheme 4. The amino group of 13 was benzylated by reductive amination and the β-carboxy group was regioselectively esterified under acidic conditions to give benzyl ester 14. The free α-carboxy group of 14 was tert-butylated and subsequently the secondary amine was protected with the phenylfluorenyl (PhFl) group to give 15. This sterically hindered group suppresses deprotonation at the α-carbon and allows enolate formation by selective deprotonation at the β-position of 15 in the subsequent step. Thus, treatment of 15 with lithium bis(trimethylsilyl)amide (LHMDS) followed by addition of methyl iodide led to exclusive methylation of the β-position to give erythro-16 and threo-16 in a ratio of 5:1. The stereoselectivity of this step can be explained by preferred formation of the (Z)-lithium enolate which adopts a hydrogen-in-plane conformation that is attacked opposite to the bulky nitrogen protecting groups. 21 The isomers erythro-16 and threo-16 were readily separated by column chromatography and the configuration of erythro-16 was verified by complete deprotection and subsequent NMR analysis 22 (see Supporting Information) as well as optical rotation measurement. 20 Hydrogenolysis of erythro-16 followed by Fmoc protection of the free amino group gave building block 7.
The phenacyl protected propargyl tyrosine building block Boc-Tyr(Prg)-OPac 8c (Prg = propargyl) was synthesized in three steps starting from Boc-Tyr-OH 17 (Scheme 5A). Double propargylation of 17 followed by saponification of the propargyl ester gave 18 that was alkylated with phenacyl bromide yielding 8c in a high yield. 8c as well as literature known 8a 17 and analogously prepared, isotopically labeled 8b were N-terminally deprotected and coupled with D-MeAsp derivative 7 to give dipeptides 5a−c (Scheme 5B).
Synthesis of Linear Heptapeptides. With all fragments in hand, heptapeptides 2a−c were assembled (Scheme 6). The C-terminal phenacyl ester of tetrapeptide 4 was reductively Under these conditions isomerization at the C-terminal Leu residue of fragment 19 is minimized as it was also reported by others. 10, 23 The hexapeptides 21a−c were N-terminally deprotected and Boc-Adda−OH 3 was coupled to give heptapeptides 2a−c. Removal of the Pac group led to macrocyclization precursors 22a−c. We found that it was essential to purify compounds 22a−c by RP-HPLC to prevent byproduct formation during the subsequent macrocyclization step.
Macrocyclization and Final Steps. The C-termini of 22a−c were activated as pentafluorophenyl (Pfp) ester and the t-butyl esters along with the Boc group were removed by TFA treatment (Scheme 7). Macrocyclization was induced under basic conditions applying a two-phase system of chloroform and phosphate buffer (pH = 9.5) to give cyclopeptides 23a−c which were purified by RP-HPLC. According to HPLC approximately 20% (in case of 23a and 23b) and 10% (in case of 23c), respectively, of an isomeric product, possibly due to epimerization at C-terminal amino acid during macrocyclization, were observed. Subsequent selenoxide elimination under mild oxidative conditions gave the desired MC derivatives 1a−c. All final products were fully characterized by one-and two-dimensional NMR spectroscopy and HRMS. The analytical data of synthetic MC-LF (1a) were identical to those of a commercial MC-LF sample confirming the structure of the synthetic material. In addition, coinjection of both a mixture of natural and synthetic 1a as well as a mixture of 1a and 1b led to single peaks in the LC-MS chromatograms (Supporting Information).
Inhibition of Protein Phosphatase-1. In order to confirm that the biological activities of synthetic and natural MC-LF are identical, we determined the potency of both compounds to inhibit the hydrolysis of p-nitrophenyl phosphate catalyzed by protein phosphatase-1 (PP1, Figure 2 ). As expected, the IC 50 values obtained with this robust assay 24 are very similar within the accuracy of this assay (synthetic 1a: IC 50 = 870 pM, natural 1a: IC 50 = 1.2 nM) further verifying the authenticity of the synthetic material. We also evaluated the inhibitory potency of the propargylated derivative 1c and its precursor 23c lacking the Michael acceptor Mdha. The similar IC 50 value of 1c (IC 50 = 1.7 nM) shows that the modification at position 4 has only a minor influence on phosphatase binding and inhibition as 
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13b Phenylselenocystein derivative 23c, lacking the capability to covalently bind to PP1, has a similar inhibitory potency (IC 50 = 2.1 nM). Our results show that neither the modification at position 4 nor the one at position 7 of the scaffold disrupt PP1 inhibition. The fact that the absence of the Michael acceptor in compound 23c does not result in reduced inhibition potency is in line with previous findings that have shown that covalent binding of the toxin to PP1 is a slow process and not required for phosphatase inhibition which is rather achieved by the initial fast noncovalent interaction. However, it is remarkable that the large side chain of NMeSecPh is tolerated during this binding process, thereby dramatically expanding the application domain of derivatized MCs.
■ CONCLUSION
In summary, we developed a novel strategy for the synthesis of MCs. Application of the Fmoc/t-Bu protecting group strategy enabled the isomerization-free synthesis of MC-LF as well as a deuterated and an alkyne-labeled derivative thereof. The incorporation of a phenylselenocysteine moiety as precursor for the Mdha residue gave access to a novel potent and reversible phosphatase inhibitor that cannot undergo covalent binding to the protein. The synthesized MC derivatives can be broadly applied for improved MC detection and quantification and pave the way for future approaches to understanding the biological roles of MCs in various organisms.
■ EXPERIMENTAL SECTION
General Experimental Methods. Technical solvents (petroleum ether and EtOAc) were distilled prior to use. THF and CH 2 Cl 2 were distilled from Na/K or CaH 2 under inert atmosphere immediately prior to use. Peptide grade DMF was used for peptide couplings. A sample of natural microcystin-LF was obtained from Enzo Life Sciences (ALX-350−081-C100, 100 μg) and used as received. The compounds 3, 16a 6, 18 8a, 17 and 10 18 were synthesized according to the literature. For the reactions performed under inert gas conditions (nitrogen) Schlenk technique and oven-dried glassware were used. Analytical thin layer chromatography (TLC) was performed using TLC silica gel 60 F 254 coated aluminum sheets (Merck). Spots were visualized either by UV light (λ = 254 nm) or by dipping and heating using ethanolic ninhydrin solution (3% w/v), aqueous potassium permanganate (1% w/v), anisaldehyde solution (135 mL EtOH, 5 mL conc. H 2 SO 4 , 15 mL glacial acetic acid, and 3.7 mL p-anisaldehyde), or Seebach's stain (25 g phosphomolybdic acid, 10 g Ce(SO 4 ) 2 · 4H 2 O, and 60 mL conc. H 2 SO 4 in 1 L H 2 O). Preparative flash column chromatography (FC) was performed using Geduran 60 silica gel (40−60 μm, Merck). NMR spectra were recorded on Bruker Avance III 400 or Bruker Avance III 600 instruments. Chemical shifts δ are reported in ppm relative to solvent signals (CDCl 3 δ H = 7.26 ppm, δ C = 77.2 ppm; CD 3 OD δ H = 3.34 ppm; δ C = 49.0 ppm; DMSO-d 6 δ H = 2.50 ppm, δ C = 39.5 ppm). For all new compounds two-dimensional NMR experiments (COSY, HSQC, and HMBC) were used for signal assignments. For numbering of carbons see Supporting Information.
Semipreparative and analytical RP-HPLC was performed using a Shimadzu LC-20A prominence system (LC-20AT pumps, SIL-20A auto sampler, CTO-20AC column oven, SPD-M2OA PDA detector, CBM-20A communication bus module and LC-Solution software). A Kinetex 5u C18 100A, AXIA (250 × 21.2 mm, Phenomenex) column was used as a stationary phase at a flow rate of 10 mL min −1 unless mentioned otherwise. LC-MS measurements were performed on a Shimadzu LCMS-2020 system (LC-20 AD high pressure pumps, SIL-20AT HAT autosampler, CTO-20AC column oven, SPD-20A UV−vis detector, CBM-20A communication bus module, LCMS-2020 ESIdetector and LC-MS-Solution software) using a Nucleodur 100−3 C18ec (4 × 125 mm, Macherey-Nagel) reversed phase column as stationary phase at a flow rate of 0.4 mL min −1 . A gradient of water with 0.1% formic acid (mobile phase A) and acetonitrile with 0.1% formic acid (mobile phase B) was used for the HPLC and LC-MS separations. Elemental analyses were performed by the microanalytical laboratory of the University of Konstanz using an Elementar vario EL instrument. HRMS measurements were performed on a Bruker micrOTOF II (ESI-TOF) or a Thermo LTQ Orbitrap Discovery (ESIOrbitrap) instrument.
General Procedures. GP1: Phenacyl Protection. 17 The amino acid derivative (1.0 equiv) is dissolved in EtOAc. Then Et 3 N (1.1 equiv) and phenacyl bromide (1.1 equiv) are added and the reaction mixture is stirred at rt for 4 h. During the reaction, the formation of a white precipitate can be observed. After 4 h the mixture is diluted with EtOAc and washed with brine (1×), sat. NaHCO 3 solution (1×), and brine (2×). The organic phase is dried over Na 2 SO 4 , filtered, and concentrated under reduced pressure.
GP2: Phenacyl Deprotection. The protected peptide is dissolved in MeOH/DMF (8:2, 8 μL mg −1 peptide). Then Mg-turnings (0.16 mg/ mg peptide) and acetic acid (0.8 μL mg −1 peptide) are added and the reaction mixture is cooled to 0°C. After 20 min cooling is removed and the reaction mixture is stirred at rt for 30 min. The reaction mixture is filtered, the volatiles are removed under reduced pressure, and the residue is taken up in CH 2 Cl 2 /MeOH (9:1). The mixture is filtered through 3 cm 3 silica column which is extensively washed with CH 2 Cl 2 /MeOH (9:1). The solvents are removed under reduced pressure and the residue is lyophilized. The obtained deprotected peptide is used without further purification.
GP3: Fmoc Deprotection. The peptide is dissolved in 5% piperidine in DMF (v/v). After 3 min, the solution is diluted with DMF and the volatiles are removed under reduced pressure. The residue is coevaporated with toluene (3×) and used without further purification.
GP4: Boc/t-Bu Deprotection. The starting material is dissolved in neat TFA and stirred at rt for 30 min. Subsequently the TFA is removed and the residue is coevaporated with toluene, EtOAc, and petroleum ether (each 1×) and used without further purification.
GP5: Fmoc Protection. The amino acid (1.0 equiv) is suspended in Na 2 CO 3 (10% w/v, 1.25 mL mmol −1 amino acid). Then Fmoc-OSu (1.3 equiv) in dioxane (1.875 mL mmol −1 amino acid) is added, and the mixture is stirred at rt overnight. The reaction mixture is diluted with H 2 O and EtOAc, acidified with aqueous NaHSO 4 (1M) to pH < 3, and extracted with EtOAc (3×). The combined organic phases are washed with brine (1×), dried over Na 2 SO 4 , filtered, and the volatiles removed under reduced pressure. The crude product is purified with FC.
GP6: Peptide Coupling. The amine and carboxylic acid are dissolved in DMF. The resulting solution is cooled to 0°C. Then base (DIPEA or collidine) and after 5 min the coupling reagent (HATU or HBTU) are added. The resulting yellowish solution is stirred at 0°C for 45 min and at rt overnight. The reaction mixture is diluted with EtOAc and washed subsequently with H 2 O, 1:1 diluted saturated citric acid solution, 1:1 diluted saturated NaHCO 3 solution, and brine (each 1×). The organic phase is dried over Na 2 SO 4 , filtered, and purified with FC.
GP7: Macrocylization. The HPLC-purified C-terminally deprotected heptapeptide (1.0 equiv) is placed in a 4 mL glass vial. Then pentafluorophenol (1.95 equiv), dissolved in freshly distilled EtOAc (24.2 mL mmol −1 peptide) and solid DCC are added. The reaction mixture is cooled to 0°C, stirred for 90 min and then at rt for 8−10 h. Afterward, the solvent is removed and the activated peptide is treated with TFA according to GP4. The resulting C-terminally activated unprotected heptapeptide is dissolved in CHCl 3 (515 mL mmol −1 peptide). The resulting solution is added dropwise over a period of 10 min to a vigorously mechanically stirred mixture of CHCl 3 (875 mL mmol −1 peptide) and pH = 9.5 phosphate buffer (1M, 875 mL mmol −1 peptide). After 30 min, the reaction mixture is diluted with a small amount of CHCl 3 and H 2 O. The phases are separated, the aqueous phase is acidified with NaHSO 4 (1M) to pH < 3 and extracted with EtOAc (3×). The organic phases are combined, washed
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GP8: Selenoxide Elimination. The macrocyclic peptide is dissolved in MeCN/H 2 O (3:2, 1 mL) and 30% aqueous H 2 O 2 (4 μL) is added. After 1h at rt, the reaction mixture is quenched with Me 2 S (50 μL) and purified by HPLC.
Synthesized Compounds (Sorted According to Compound Number). Microcystin-LF (1a). The C-terminally unprotected heptapeptide 22a (15 mg, 10.9 μmol) was macrocyclized using pentafluorophenol (4.0 mg, 21.3 μmol) and DCC (2.8 mg, 13.3 μmol) according to GP7. The crude macrocycle 23a was purified by semipreparative RP-HPLC (gradient: 60−90% B in 30 min, t R = 13.3 min). The cyclic peptide 23a was transformed to 1a according to GP8 and the reaction mixture was separated by semipreparative RP-HPLC (gradient: 50−70% B in 20 min, t R = 13.2 min). MC-LF 1a was obtained as a white amorphous solid (2.0 mg, 19%). LC-MS analysis of synthetic 1a coinjected with natural MC-LF resulted in a single peak with the expected mass ( Figure S3 [Phe-d 5 4 ]-Microcystin-LF (1b). The macrocyclic derivative 23b (5 mg, 4.35 μmol) was transformed to 1a according to GP8, and the reaction mixture was separated by semipreparative RP-HPLC (gradient: 50−70% B in 20 min, t R = 13.6 min). The microcystin 1b was obtained as a white amorphous solid (3.3 mg, 76%). LC-MS analysis of synthetic 1b coinjected with MC-LF resulted in a single peak with the expected masses of both deuterated 1b and undeuterated MC-LF ( Figure S4 Fmoc-γ-D-Glu(Ot-Bu)-N-MeSecPh-D-Ala-Leu-OPac (4). Tripeptide 12 (297 mg, 449.5 μmol) was deprotected according to GP4. The Nterminally deprotected tripeptide (91 mg, 107.5 μmol) and Fmoc-DGlu-Ot-Bu (249 mg, 584.4 μmol) were dissolved in DMF (2 mL). Peptide coupling was performed according to GP6 using HATU (222 mg, 584.4 μmol) and DIPEA (313 μL, 1.8 mmol). The crude product was purified by FC to give tetrapeptide 4 (390 mg, 90%) as a white Fmoc-D-MeAsp-Ot-Bu (7). The amino acid erythro-16 (1.00 g, 1.6 mmol) was suspended in methanol (13 mL) and 10% Pd/C catalyst (410 mg, wet, 53.7% water) was added. The reaction mixture was hydrogenated overnight at slightly positive hydrogen pressure and filtered through a Celite pad. The residue was further treated according to GP5 using Fmoc-OSu (703 mg, 2.084 mmol), dioxane (3 mL) and 10% w/v aqueous Na 2 CO 3 (2 mL). The crude product was purified with FC (petroleum ether/EtOAc/AcOH 74:25:1) to give 7 (572 mg, 84%) as a white amorphous solid: R f = 0. + Calcd for C 25 H 28 NO 6 : 438.19111; Found 438.19216; Anal. Calcd for C 25 H 27 NO 6 : C, 68.64; H, 6.22; N, 3.20. Found: C, 68.56; H, 6.11; N, 3.32. Boc-N-MeSecPh-D-Ala-Leu-OPac (12). 18 Boc-Leu-OPac 17 (500 mg, 1.43 mmol) was deprotected according to GP4. Then H-Leu-OPac, Boc-D-Ala-OH (325 mg, 1.72 mmol) and HOBt (232 mg, 1.72 mmol) were dissolved in CH 2 Cl 2 (5 mL) and coupled according to GP6 using HBTU (651 mg, 1.72 mmol) and DIPEA (980 μL, 5.72 mmol). The crude product was purified by FC to give Boc-D-Ala-Leu-OPac 18 (500 mg, 83%) as a white solid: R f = 0.66 (PE/EtOAc 1:1); The analytical data for Boc-D-Ala-Leu-OPac were in agreement with the published ones. 18 The dipeptide Boc-D-Ala-Leu-OPac (502 mg, 1.195 mmol) was deprotected according to GP4 to give H-D-Ala-Leu-OPac 11 that was immediately used in the next step. Crude deprotected dipeptide 11 (1.195 mmol) and Boc-NMeSecPh−OH 6 (471 mg, 1.314 mmol) were dissolved in DMF (5 mL) and coupled according to GP6 using HATU (500 mg, 1.314 mmol) and DIPEA (832 μL, 4.778 mmol). The crude product was purified by FC (petroleum ether/EtOAc 1:1) to give title compound 12 (683 mg, 90%) as a white amorphous solid. The analytical data for 12 were in agreement with the published ones. 18 
1
H NMR (400 MHz, CDCl 3 ) δ 7. J = 8.5, 1.3 Hz, 2H, Ar), 7.62 (dt, J = 7.5, 1.3 Hz, 1H, Ar), 4H, Ar), 3H, Ar), 6.79 (b, 1H, NH Leu), 6.53 (b, 1H, NH Ala), 5.47 (d, J = 16.3 Hz, 1H , CH 2 Pac), 5.22 (d, J = 16.3 Hz, 1H, CH 2 Pac), 4.69 (b, 1H, 4.50 (b, 2H, 3.60 (dd, J = 13.0, 5.9 Hz, 1H, 3.16 (b, 1H, , 2.80 (s, 3H, -NMe), 1.90−1.66 (m, 3H, 2xH-β Leu, H-γ Leu), 1.45 (s, 9H, t Bu), 1.38 (d, J = 6.9 Hz, 1H, Ala), 0.99 (d, J = 6.3, Hz, 3H, CH 3 Leu), 0.97 (d, J = 6.3 Hz, 3H, CH 3 Leu) .
Bn-D-Asp(OBn)−OH (14) . Starting from Bn-D-Asp-OH (8.61 g, 38.6 mmol), compound 14 (10.16 g, 84%) was prepared according to a procedure published for the synthesis of Bn-L-Asp(OBn)−OH. 25 The analytical data of 14 were in agreement with the data published for its enantiomer. 25 Bn-D-Asp(OBn)-Ot-Bu. Bn-D-Asp(OBn)−OH 14 (4.0 g, 12.8 mmol) was suspended in t-BuOAc (72 mL) and 70% aqueous perchloric acid (1.840 mL, 15.2 mmol) was added dropwise. After stirring for 18 h at rt, water (40 mL) was added and the phases were separated. The aqueous phase was extracted with EtOAc (1× 30 mL). The organic phases were combined and washed with saturated NaHCO 3 solution (3×). During the workup, formation of a white precipitate could be observed. The organic phase was filtered, washed with brine and dried with Na 2 SO 4 . The volatiles were removed and Bn-D-Asp(OBn)-Ot-Bu was obtained as a pale yellow oil (3. 168 g, 67%) . The analytical data for Bn-D-Asp(OBn)-Ot-Bu were in agreement with the data published for its enantiomer. 25 (2R)-4-Benzyl-1-tert-butyl-N-benzyl-N-(9-phenylfluoren-9-yl)-aspartate (15) . To the solution of Bn-D-Asp(OBn)-Ot-Bu (1.587 g, 4.274 mmol) in dry acetonitrile (47 mL) anhydrous K 3 PO 4 (1.088 g, 5.192 mmol) and phenylfluorenyl bromide (1.324 g, 4. 122 equiv) were added. The resulting heterogenic mixture was mechanically stirred for 24 h at rt, filtered, and the solvent was removed. The crude product was purified by FC to give 15 (1.870 g, 72%) as a white solid. The analytical data for 15 were in agreement with the data published for its enantiomer. 25 (15 mL) and then a solution of methyl iodide (707 μL, 11.35 mmol) in dry THF (11 mL) was added slowly. The mixture was stirred for 3 h at < −20°C and 30 min at room temperature and quenched with sat. aqueous NH 4 Cl (10 mL) and water (10 mL). The phases were separated and the aqueous phase was extracted with EtOAc (100 mL). The combined organic phases were washed with brine (1×), dried over Na 2 SO 4 , filtered, and the solvents were removed. The crude product was purified by FC to give eryhtro-16 (1. The Journal of Organic Chemistry H-β-D-MeAsp-OH, ((3S)-β-D-methylaspartic Acid). The amino acid erythro-16 (200 mg, 1.6 mmol) was suspended in methanol (2.84 mL) and 10% Pd/C catalyst (82 mg, wet, 53.7% water) was added. The reaction mixture was hydrogenated overnight at a slightly positive hydrogen pressure and filtered through a syringe filter. The filtrate was diluted 1:1 with aqueous HCl (0.1 M) and filtered twice through a syringe filter. The volatiles were removed and the residue was coevapotated with EtOAc (1×) and toluene (2×). The resulting solid was treated with TFA (0.7 mL) according to GP4. The crude product was purified by HPLC (1% B isocratic over 10 min, t R = 4. N-(tert-Butoxycarbonyl)-O-prop-2-yn-1-yl-L-tyrosine (Boc-Tyr-(Prg)−OH) (18) . 27 2-tert-Butoxycarbonylamino-3-[4-(prop-2-ynyloxy)-phenyl]-propionic acid propargyl ester 28 (3.633 g, 10. 17 mmol) was dissolved in 1 M KOH solution in methanol (20.34 mL, 20.34 mmol) and sonicated for 2 h at 35°C. The methanol was removed under reduced pressure. The residue was dissolved in H 2 O (30 mL) and the aqueous phase was washed with Et 2 O (2 × 30 mL). The aqueous phase was acidified with KHSO 4 (1 M) to pH = 2 and extracted with EtOAc (2 × 30 mL). The EtOAc extracts were combined, washed with brine, dried over MgSO 4 , and the volatiles were removed under reduced pressure. Product 18 was obtained as a white amorphous solid (3.1 g, 95%) and used without further purification. The analytical data for 18 were in agreement with the published ones. 27 1 H NMR (400 MHz, CDCl 3 ) δ 7.12 (d, J = 8.5 Hz, 2H, Ar), 6.92 (d, J = 8.6 Hz, 2H, Ar), 4.92 (d, J = 7.0 Hz, 1H, NH), 4.92 (d, J = 2.4 Hz, 2H, -OCH 2 ), 4.56 (b, 1H, H-α) , 3.14 (dd, J = 13.9, 5.2 Hz, 1H, H-β), 3.04 (dd, J = 13.8, 5.5 Hz, 1H, H-β), 2.51 (t, J = 2.3 Hz, 1H, -CCH), 1.42 (s, 9H, .
Fmoc-γ-D-Glu(Ot-Bu)-N-MeSecPh-D-Ala-Leu-β-D-MeAsp(Ot-Bu)-Phe-OH (21a). Tetrapeptide 4 (61 mg, 63 μmol) and dipeptide 5a (50 mg, 72 μmol) were deprotected according to GP2 and GP3, respectively. The products 19 and 20a were dissolved in DMF (1 mL) and coupled according to GP6 using HATU (28 mg, 74 μmol) and collidine (25 μL, 188 μmol) . The crude product was purified by Fmoc-γ-D-Glu(Ot-Bu)-N-MeSecPh-D-Ala-Leu-β-D-MeAsp(Ot-Bu)-Phe-d 5 −OH (21b). Tetrapeptide 4 (150 mg, 164.5 μmol) and dipeptide 5b (110 mg, 158.1 μmol) were deprotected according to GP2 and GP3, respectively. The crude peptides 19 and 20b were dissolved in DMF (1 mL) and coupled according to GP6 using HATU (90 mg, 237.2 μmol) and collidine (160 μL, 1207 μmol). The crude product was purified by FC (CH 2 Cl 2 /i-PrOH 99:1 to 95:5) to give 21b (180 mg, 87%) as a white amorphous solid: R f = 0.65 (CH 2 Cl 2 /iPrOH 95:5); The 1 H NMR spectrum (400 MHz) recorded at 300 K showed two sets of signals (ratio approximately 5:1) and peak broadening due to the occurrence of two rotamers of the Nmethylated amide bond; due to incomplete H/D-exchange some remaining NH-protons are visible.
